Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Izanne Roos; Emmanuelle Leray; Federico Frascoli; Romain Casey; J William L Brown; Dana Horakova; Eva K Havrdova; Maria Trojano; Francesco Patti; Guillermo Izquierdo; Sara Eichau; Marco Onofrj; Alessandra Lugaresi; Alexandre Prat; Marc Girard; Pierre Grammond; Patrizia Sola; Diana Ferraro; Serkan Ozakbas; Roberto Bergamaschi; Maria Jose Sa; Elisabetta Cartechini; Cavit Boz; Franco Granella; Raymond Hupperts; Murat Terzi; Jeannette Lechner-Scott; Daniele Spitaleri; Vincent Van Pesch; Aysun Soysal; Javier Olascoaga; Julie Prevost; Eduardo Aguera-Morales; Mark Slee; Tunde Csepany; Recai Turkoglu; Youssef Sidhom; Riadh Gouider; Bart Van Wijmeersch; Pamela McCombe; Richard Macdonell; Alasdair Coles; Charles B Malpas; Helmut Butzkueven; Sandra Vukusic; Tomas Kalincik

Journal article

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horakova, Eva K Havrdova, Maria Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Grammond, Patrizia Sola, Diana Ferraro, Serkan Ozakbas, Roberto Bergamaschi Show all

BRAIN | OXFORD UNIV PRESS | Published : 2020

DOI: 10.1093/brain/awaa231

Abstract

In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the time required to attain maximal effect is unclear. In this study we aimed to develop a method that allows identification of the time to manifest fully and clinically the effect of multiple sclerosis treatments (‘therapeutic lag’) on clinical disease activity represented by relapses and progression-of-disability events. Data from two multiple sclerosis registries, MSBase (multinational) and OFSEP (French), were used. Patients diagnosed with multiple sclerosis, minimum 1-year exposure to treatment, minimum 3-year pretreatment follow-up and..

View full abstract

University of Melbourne Researchers

Helmut Butzkueven Author Medicine - Royal Melbourne Hospital

Tomas Kalincik Author Medicine - Royal Melbourne Hospital

Charles Malpas Author Medicine - Royal Melbourne Hospital

Izanne Roos Author Medicine - Royal Melbourne Hospital

Related Projects (3)

BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Grants

Awarded by NHMRC

Awarded by Agence Nationale de la Recherche

Funding Acknowledgements

This study was supported by the EDMUS Foundation, Biogen and NHMRC (1140766, 1129189, 1157717). I.R. is supported by a MSIF-ARSEP McDonald fellowship grant and a Melbourne Research Scholarship. The MSBase Foundation is a not-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva and Sanofi Genzyme. The Observatoire Francais de la Sclerose en Plaques (OFSEP) is supported by a grant provided by the French State and handled by the 'Agence Nationale de la Recherche,' within the framework of the 'Investments for the Future' program, under the reference ANR-10-COHO-002, by the Eugene Devic EDMUS Foundation against multiple sclerosis and by the ARSEP Foundation. The study was conducted separately and apart from the guidance of the sponsors.